TRVI
Trevi Therapeutics, Inc.
Key Financials
Net Income
$-42759000
↑ 10.8%
Operating Income
$-49328000
↑ 4.3%
Total Assets
$193.4M
↑ 74.4%
EPS (Diluted)
$-0.32
↑ 31.9%
Shareholders' Equity
$183.2M
↑ 83.9%
Total Liabilities
$10.2M
↓ 9.4%
Cash & Equivalents
$18.9M
↓ 44.5%
Operating Cash Flow
$-42089000.00
↓ 10.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 424B5 | 4/17/2026 | View on SEC |
| 8-K | 4/17/2026 | View on SEC |
| 424B5 | 4/16/2026 | View on SEC |
| PRE 14A | 4/10/2026 | View on SEC |
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| 10-K | 3/17/2026 | View on SEC |
| 8-K | 3/17/2026 | View on SEC |
| 8-K | 3/9/2026 | View on SEC |
| 4 | 2/20/2026 | View on SEC |
| 4 | 2/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TRVI |
| Company Name | Trevi Therapeutics, Inc. |
| CIK | 1563880 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 203-304-2499 |